keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/29331031/comparative-study-of-efficacy-and-safety-between-bladder-body-and-trigonal-intravesical-onabotulinumtoxina-injection-in-the-treatment-of-interstitial-cystitis-refractory-to-conventional-treatment-a-prospective-randomized-clinical-trial
#1
Yuan-Hong Jiang, Jia-Fong Jhang, Cheng-Ling Lee, Hann-Chorng Kuo
PURPOSE: Intravesical onabotulinumtoxinA (BoNT-A) injection can relieve symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS). However, the therapeutic efficacy of different injection sites is not well known. This study compared therapeutic efficacy and safety between bladder body and trigonal BoNT-A injection. MATERIALS AND METHODS: Patients were randomly treated with 100U of BoNT-A in 10 mL saline injected into 20 bladder body sites or 10 trigonal sites...
January 13, 2018: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/29330071/onabotulinumtoxina-for-the-treatment-of-post-stroke-distal-lower-limb-spasticity-a-randomized-trial
#2
Theodore Wein, Alberto Esquenazi, Wolfgang H Jost, Anthony B Ward, Grace Pan, Rozalina Dimitrova
BACKGROUND: Post-stroke distal lower limb spasticity impairs mobility, limiting activities of daily living, requiring additional caregiver time. OBJECTIVE: To evaluate the efficacy, safety, and sustained benefit of onabotulinumtoxinA in adults with post-stroke lower limb spasticity (PSLLS). DESIGN: A multicenter, randomized, double-blind, phase 3, placebo-controlled trial. SETTING: 60 study centers across North America, Europe, Russia the United Kingdom, and South Korea...
January 9, 2018: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/29329897/-botulinium-toxin-and-idiopathic-overactive-bladder-multicentric-contempory-management-in-bourgogne
#3
A Schneider, B Tourlonias, L Cormier, E Mourey, N Koutlidis, E Delorme, J Pasquale, I Kermarec, A-D Foahom-Kamwa, V Bonniaud
INTRODUCTION: Since 2014, OnabotulinumtoxinA Botox® (Allergan, Inc., Irvine, USA) represents a new therapeutic option for second-line treatment of idiopathic overactive bladder. The purpose of the current study was to evaluate practices of surgeons using onabotulinium toxin (BoNTA) in this indication. MATERIAL AND METHODS: All urogynecology centers of the country were asked in order to list all patients who were treated since marketing autorisation. Patient symptoms, previous treatments, paraclinic evaluations, data of surgery and the characteristics of the follow up were collected and analyzed...
January 9, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29322261/the-journey-from-genetic-predisposition-to-medication-overuse-headache-to-its-acquisition-as-sequela-of-chronic-migraine
#4
EDITORIAL
Paolo Martelletti
Migraine remains one of the biggest clinical case to be solved among the non-communicable diseases, second to low back pain for disability caused as reported by the Global Burden of Disease Study 2016. Despite this, its genetics roots are still unknown. Its evolution in chronic forms hits 2-4% of the population and causes a form so far defined Medication Overuse Headache (MOH), whose pathophysiological basis have not been explained by many dedicated studies. The Global Burden of Disease Study 2016 has not recognized MOH as independent entity, but as a sequela of Chronic Migraine...
January 10, 2018: Journal of Headache and Pain
https://www.readbyqxmd.com/read/29296045/current-pharmacological-and-surgical-treatment-of-underactive-bladder
#5
REVIEW
Yuan-Hong Jiang, Cheng-Ling Lee, Jia-Fong Jhang, Hann-Chorng Kuo
Underactive bladder (UAB) or detrusor underactivity (DU) is a common yet still poorly understood urological problem. In addition to true detrusor failure and neuropathy, the inhibitory effects of detrusor contraction by the striated urethral sphincter and the bladder neck through alpha-adrenergic activity may also play a role in the development of UAB or DU. Treatment of UAB or DU aims to reduce the postvoid residual (PVR) urine volume and increase voiding efficiency, either by spontaneous voiding or abdominal straining...
October 2017: Ci Ji Yi Xue za Zhi, Tzu-chi Medical Journal
https://www.readbyqxmd.com/read/29280408/optimizing-the-long-term-management-of-chronic-migraine-with-onabotulinumtoxina-in-real-life
#6
Cristina Tassorelli, Gioacchino Tedeschi, P Sarchielli, Luigi Alberto Pini, Licia Grazzi, Pierangelo Geppetti, Marina De Tommaso, Marco Aguggia, P Cortelli, Paolo Martelletti
Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education...
December 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29244069/impact-of-comprehensive-minimally-invasive-multimodal-aesthetic-treatment-on-satisfaction-with-facial-appearance-the-harmony-study
#7
Susan H Weinkle, W Philip Werschler, Craig F Teller, Jonathan M Sykes, Ava Shamban, Alexander Rivkin, Vic A Narurkar, Michael S Kaminer, Steven Dayan, Joel L Cohen, Conor J Gallagher
Background: Individuals seeking aesthetic treatment have concerns regarding multiple facial areas. Objectives: Assess the aesthetic impact and satisfaction achieved with a multimodal approach to aesthetic treatment using a combination of minimally invasive treatments. Methods: Prospective, multicenter, rater-blinded, 4-month HARMONY study evaluated patient satisfaction and aesthetic impact of a combination of fillers (VYC-20L, HYC-24L, and HYC-24L+), onabotulinumtoxinA, and bimatoprost...
December 13, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/29238711/long-term-dose-stability-of-onabotulinumtoxina-injection-for-adductor-spasmodic-dysphonia-a-19-year-single-institution-experience
#8
Paul Paddle, Inna Husain, Christine Moniz, Scott Turner, Ramon Arturo Franco
Objectives: Adductor spasmodic dysphonia (AdSD) is a focal dystonia predominantly involving the laryngeal adductor muscles. AdSD is reported to be a largely non-progressive neurological disorder, though fluctuations in symptom severity do occur. Repeated laryngeal onabotulinumtoxinA (BTX-A) injections are the primary management for AdSD. A number of studies have demonstrated long-term dose stability as evidence of this long-term disease stability. Methods: A retrospective review was performed on all patients undergoing BTX-A injections for AdSD from April 1994 to September 2013 by a single laryngologist at a tertiary referral laryngology center...
2017: Frontiers in Surgery
https://www.readbyqxmd.com/read/29230798/botulinum-toxin-type-a-therapy-for-cervical-dystonia
#9
REVIEW
Mafalda Castelão, Raquel E Marques, Gonçalo S Duarte, Filipe B Rodrigues, Joaquim Ferreira, Cristina Sampaio, Austen P Moore, João Costa
BACKGROUND: This is an update of a Cochrane Review first published in 2005. Cervical dystonia is the most common form of focal dystonia and is a highly disabling movement disorder characterised by involuntary, usually painful, head posturing. Currently, botulinum toxin type A (BtA) is considered the first line therapy for this condition. OBJECTIVES: To compare the efficacy, safety, and tolerability of botulinum toxin type A (BtA) versus placebo in people with cervical dystonia...
December 12, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29204191/onabotulinumtoxina-in-the-treatment-of-patients-with-chronic-migraine-clinical-evidence-and-experience
#10
REVIEW
Chia-Chun Chiang, Amaal J Starling
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4-2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials...
December 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29171146/onabotulinumtoxina-in-chronic-migraine-predictors-of-response-a-prospective-multicentre-descriptive-study
#11
Clara Domínguez, Patricia Pozo-Rosich, Marta Torres-Ferrús, Natalia Hernández-Beltrán, Carmen Jurado-Cobo, Carmen González-Oria, Sonia Santos, María José Monzón, Germán Latorre, Luis Carlos Álvaro, Ana Gago, Mercedes Gallego, Vicente Medrano, Mariano Huerta, Jessica García-Alhama, Roberto Belvís, Yago Leira, Rogelio Leira
BACKGROUND: OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in the real-life setting and to identify clinical predictors of outcome. METHODS: We designed a prospective multicentre study performed in 13 Hospitals in Spain. Patients underwent a complete medical history and examination. They received treatment with OnabotulinumtoxinA every 12 weeks over a year...
November 24, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29169811/evidence-of-and-experience-with-the-use-of-onabotulinumtoxina-in-trigeminal-neuralgia-and-primary-headaches-other-than-chronic-migraine
#12
S Santos-Lasaosa, M L Cuadrado, A B Gago-Veiga, A L Guerrero-Peral, P Irimia, J M Láinez, R Leira, J Pascual, J Porta-Etessam, M Sánchez Del Río, J Viguera Romero, P Pozo-Rosich
INTRODUCTION: In the field of headaches, onabotulinumtoxinA (onabotA) is well established as a treatment for chronic migraine (CM). In recent years, it has been used increasingly to treat other primary headaches (high-frequency episodic migraine, trigeminal-autonomic cephalalgias, nummular headache) and trigeminal neuralgia. As this treatment will progressively be incorporated in the management of these patients, we consider it necessary to reflect, with a fundamentally practical approach, on the possible indications of onabotA, beyond CM, as well as its administration protocol, which will differ according to the type of headache and/or neuralgia...
November 20, 2017: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29169810/evidence-and-experience-with-onabotulinumtoxina-in-chronic-migraine-recommendations-for-daily-clinical-practice
#13
A B Gago-Veiga, S Santos-Lasaosa, M L Cuadrado, Á L Guerrero, P Irimia, J M Láinez, R Leira, J Pascual, M Sanchez Del Río, J Viguera, P Pozo-Rosich
OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients...
November 20, 2017: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29166305/botulinum-toxin-therapy-is-syringe-type-related-to-cost-effectiveness
#14
Mark Anthony Foglietti, Lauren Wright, Alanna Foglietti-Fostyk
INTRODUCTION: Clostridium botulinum toxin is effective through cleaving presynaptic proteins at the neuromuscular junction, which prevents the release of acetylcholine and inhibits muscle contraction. Several serotypes of botulinum toxin (BT) exist; however, only 2 types have been approved by the US Food and Drug Administration for commercial and medical use, A and B. Both types of BT must be administered intramuscularly with a syringe, but the type of syringe is the injector's preference...
November 21, 2017: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/29163347/long-term-treatment-benefits-and-prolonged-efficacy-of-onabotulinumtoxina-in-patients-affected-by-chronic-migraine-and-medication-overuse-headache-over-3%C3%A2-years-of-therapy
#15
Simona Guerzoni, Lanfranco Pellesi, Carlo Baraldi, Michela Maria Cainazzo, Andrea Negro, Paolo Martelletti, Luigi Alberto Pini
Background: Chronic migraine (CM) affects about the 2% of the general population and it has been recognized as one of the most-disabling conditions worldwide by the World Health Organization. CM is often associated with the overuse of abortive medication, which determines the worsening of headache itself and the development of a secondary headache called medication overuse headache. The management of these associated conditions is difficult, but a growing amount of evidence is pointing out the effectiveness and the good safety profile of OnabotulinumtoxinA (OnabotA)...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/29124347/the-effect-of-onabotulinumtoxina-according-to-site-of-injection-in-patients-with-overactive-bladder-a-systematic-review-and-meta-analysis
#16
Jung Ki Jo, Kyu Nam Kim, Dong Won Kim, Yong Tae Kim, Ji Yoon Kim, Ji Yeon Kim
PURPOSE: This study assessed the efficacy and safety of onabotulinumtoxinA according to injection site for treatment of overactive bladder. METHODS: A systematic literature review located randomized controlled trials of onabotulinumtoxinA treatment for neurogenic detrusor overactive bladder and idiopathic overactive bladder in adults. We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the Ovid platform. Meta-analysis was based on Cochrane Review Methods...
November 9, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29067433/urinary-incontinence-in-women-a-review
#17
REVIEW
Emily S Lukacz, Yahir Santiago-Lastra, Michael E Albo, Linda Brubaker
Importance: Urinary incontinence, the involuntary loss of urine, is a common health condition that may decrease quality of life. Ten to twenty percent of women and up to 77% of women residing in nursing homes have urinary incontinence, yet only 25% seek or receive treatment. Observations: This review summarizes the evaluation and therapeutic options for women affected by urinary incontinence. The initial assessment should focus on understanding the effect of incontinence on quality of life, the patient's goals and preferences for treatment, the results of previous treatments, and the presence of concomitant conditions, such as advanced pelvic organ prolapse, that may require referral...
October 24, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29064991/efficacy-of-incobotulinumtoxina-for-the-treatment-of-glabellar-frown-lines-in-male-subjects-post-hoc-analyses-from-randomized-double-blind-pivotal-studies
#18
RANDOMIZED CONTROLLED TRIAL
Derek H Jones, Martina Kerscher, Thorin Geister, Michael A Hast, Petra Weissenberger
BACKGROUND: Males are increasingly seeking minimally invasive cosmetic procedures such as botulinum toxin injection. However, few studies have specifically examined the efficacy of such procedures among men. OBJECTIVE: To assess the efficacy of incobotulinumtoxinA for treating glabellar frown lines (GFLs) in men. METHODS: Three incobotulinumtoxinA studies were included in post hoc analyses of responder rates: 2 pivotal Phase 3 US registration studies for GFLs (n = 55 males in a pooled analysis) and a European pivotal Phase 3 study for upper facial lines (UFLs; n = 21 males)...
November 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/29031894/refractory-urgency-urinary-incontinence-treatment-in-women-impact-of-age-on-outcomes-and-complications
#19
Yuko M Komesu, Cindy L Amundsen, Holly E Richter, Stephen W Erickson, Mary F Ackenbom, Uduak U Andy, Vivian W Sung, Michael Albo, W Thomas Gregory, Marie Fidela Paraiso, Dennis Wallace
BACKGROUND: Women with refractory urgency urinary incontinence (ie, unresponsive to behavioral and pharmacological interventions) are treated with onabotulinumtoxinA or sacral neuromodulation. OBJECTIVE: The objective of the study was to compare treatment efficacy and adverse events in women <65 and ≥65 years old treated with onabotulinumtoxinA or sacral neuromodulation. STUDY DESIGN: This study was a planned secondary analysis of a multicenter, randomized trial that enrolled community-dwelling women with refractory urgency urinary incontinence to onabotulinumtoxinA or sacral neuromodulation treatments...
October 12, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29031769/intra-trigonal-onabotulinum-toxin-a-improves-bladder-symptoms-and-quality-of-life-in-bladder-pain-syndrome-interstitial-cystitis-patients-a-pilot-single-centre-randomized-double-blind-placebo-controlled-trial
#20
R Pinto, D Costa, A Morgado, P Pereira, A Charrua, J Silva, F Cruz
PURPOSE: To compare efficacy and safety of trigonal injections of onabotulinumtoxinA and saline in Bladder Pain Syndrome/Interstitial Cystitis patients. MATERIALS AND METHODS: This phase II study enrolled women with Bladder Pain Syndrome/Interstitial Cystitis >6months and pain ≥4 in 0-10 visual analogue scale, refractory to common treatment. OnabotulinumtoxinA 100U (n=10) or saline (placebo, n=9), were administered as 10 trigonal injections of 1ml. Primary end-point was change from baseline in pain intensity reported at week 12...
October 12, 2017: Journal of Urology
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"